Drug Trial Radar · NCT02013245
Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.
Last checked: Nov 19, 2026Latest source record: Mar 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jan 2013
Primary completion
Jun 2014
Study completion Nov 2014
Sponsor
- Lead sponsor
- Biofabri, S.LIndustry
- Sponsor type
- Industry
- Collaborators
- Universidad de Zaragoza; Centre Hospitalier Universitaire Vaudois; TuBerculosis Vaccine Initiative
- First posted
- Dec 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety and immunogenicity of MTBVAC as a potential substitute for BCG vaccination. BCG vaccination has indeed demonstrated its major limitation in inducing protection against tuberculosis (TB). Novel vaccines are essential to fight against the current world epidemics in tuberculosis and resistance to anti-TB drugs.
Conditions
- Tuberculosis
- Healthy
Interventions
MTBVAC live vaccineBiological
Live-attenuated Mycobacterium tuberculosis vaccine
Commercially available BCG live vaccineBiological
Live-attenuated Mycobacterium bovis vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events up to 210 Days After VaccinationTime frame: 7 months follow up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.